Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Glioblastoma multiforme (GBM) is a deadly brain cancer with high infiltration, making surgical removal challenging.
• Developing anticancer agents with anti-invasive and antimigratory properties is crucial for improving patient survival.
• Metformin, a diabetes medication, has demonstrated potential as an anticancer agent.

Purpose of the Study:

• To investigate the anticancer potential of metformin against glioblastoma.
• To evaluate metformin's effects on GBM cell motility, invasion, and survival.
• To elucidate the mechanism of action, including AKT pathway involvement.

Main Methods:

• Treatment of SF268 and U87 glioblastoma cell lines with metformin.
• Assessment of cell survival, 2D cell motility, and cell invasion.
• Analysis of cellular adhesion and AKT phosphorylation levels.

Main Results:

• Metformin significantly decreased the survival of SF268 glioblastoma cells.
• Metformin inhibited 2D cell motility and invasion in SF268 and U87 cells.
• Metformin treatment increased cellular adhesion and inactivated AKT by reducing phosphorylation.

Conclusions:

• Metformin exhibits significant anticancer effects against glioblastoma.
• Metformin possesses anti-invasive and antimetastatic potential in glioblastoma models.
• The study highlights metformin's mechanism involving AKT inactivation and modulation of cell adhesion.